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ABSTRACT 
The age at diagnosis of 242 girls with Turner syndrome (TS) treated in Belgium with growth 
hormone between 1991 and 2002 was evaluated. The median (range) age at diagnosis was 6.6 (0-
18.3) years. Patients with 45,X karyotype were diagnosed earlier than patients with other 
karyotypes. Compared to a previous survey, performed on 100 patients 12 years earlier, more 
patients were diagnosed during infancy and childhood, and less during adolescence. However, in 
22% of the girls the diagnosis was made after the age of 12 years; these girls showed the largest 
height deficit. As early diagnosis has several potential advantages we recommend that a 
cytogenetic analysis should be considered in all girls with unexplained short stature with height 
below -2 SD of the mean for age or below the parent specific lower limit of height. 
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Growth retardation and short stature are the main characteristics of Turner syndrome (TS), a 
chromosomal disorder with a large spectrum of manifestations. 
Treatment of TS girls with recombinant human growth hormone (GH) increases adult height.1-3 
Although it is not clear whether early initiation of GH treatment will result in a taller final height, if 
started at a relatively young age height can be normalised during childhood, allowing an age 
appropriate start of oestrogen therapy for puberty induction.1 2 Timely initiation of GH treatment 
requires early diagnosis, but the diagnosis of TS, however, is often late.4 5 
In the present study we tested the hypothesis that the availability of growth promoting treatment 
has increased the watchfulness for the diagnosis of TS in short girls, resulting in an earlier 
diagnosis. For this purpose we evaluated the age at diagnosis of all TS girls who started GH 
treatment between 1991 and 2002, and we compared the results with those of our previous survey 
published in 1991.4 
SUBJECTS AND METHODS 
From the database of the Belgian Study group for Paediatric Endocrinology, containing the data of 
approximately 95% of all children treated with GH in Belgium since 1987, we retrieved all TS 
patients who started GH treatment between 1991 (the first year after the registration of GH therapy 
for TS in Belgium) and 2002. Two hundred and forty two girls with TS were included: 113 patients 
(47%) had the 45,X karyotype, the remainder had various mosaicisms or structural anomalies of 
one X chromosome. The age at which the diagnostically cytogenetic examination was performed 
was considered as the age at diagnosis. In patients aged 1 year or older, height at diagnosis was 
expressed as standard deviation score (SDS) using the Tanner 1965 references.6 7 Results are 
expressed as absolute numbers (percentages), median (range), or mean (SD) values. The results for 
patients with the 45,X karyotype were compared with those with other karyotypes. The obtained 
results were also compared with those of our previous survey on 100 TS patients, not treated with 
GH, referred to the Division of Paediatric Endocrinology of the University of Leuven, Belgium, 
between 1972 and 1988.4 Observed numbers were compared by the x2 test. Comparisons between 
groups were done with the Mann- Witney U test. 
RESULTS 
Table 1 shows the results in comparison to our previous survey. For the whole group, the median 
age at diagnosis was 6.6 years, and ranged from prenatal life to 18.3 years. Patients with the 45,X 
karyotype were diagnosed earlier than patients with other karyotypes (1.2 v 9.6 years; p < 0.001). 
Seventy three (30%) of the patients were diagnosed before the age of 1 year, of whom four were 
diagnosed prenatally, 115 (48%) were detected in childhood (1-12 years), and 54 (22%) in 
adolescence (>12 years). Patients with the 45,X karyotype were more frequently diagnosed before 
the age of 1 year, often due to the presence of oedema, dysmorphic features, or a cardiopathy. In 
the patients diagnosed after the age of 1 year, the median age at diagnosis was 10.1 years; there 
was no difference between the patients with the 45,X karyotype or the other karyotypes. 
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Compared to our previous analysis, the median age at diagnosis was significantly younger for the 
whole group of patients, as well as for the patients diagnosed beyond the age of 1 year. More 
patients were diagnosed in infancy and childhood, and less during adolescence, illustrating a 
significant age shift to earlier diagnosis (x2 19.8; p < 0.0001). 
In the present survey the mean (SD) height at diagnosis was -2.40 (0.93) SDS, which is less short 
than in our previous survey (-2.90 (1.00) SDS; p < 0.001). The height deficit was more important in 
the adolescent girls. Below the age of 6 years 47% of the patients were shorter than -2 SDS, while in 
the adolescent girls 87% were smaller than -2 SDS. There were no differences between the patients 
with the 45,X karyotype and the others. 
DISCUSSION 
In our present survey the median age at diagnosis of TS was 6.6 years, which is significantly earlier 
than the age of diagnosis a decade ago.4 More patients were diagnosed during infancy and 
childhood, which is a favourable trend. This may be due to an increased awareness for the 
diagnosis of TS in short girls since the availability of growth promoting treatment and the many 
related publications. Moreover, advances in prenatal diagnostics and genetics may also contribute 
to this trend. 
However, our data also show that in this cohort, about 20% of the girls with TS are diagnosed 
beyond the age of 12 years, most of them with a serious height deficit. These patients have missed 
the opportunity of early GH treatment, enabling normalisation of height during childhood and age 
appropriate induction of puberty.1 As our present survey is based on TS patients treated with GH, 
and as GH treatment in girls with TS in Belgium is usually started after the age of 6 years,1 patients 
not yet treated with GH are not included in the present survey and probably more patients are 
currently diagnosed at an earlier age. On the other hand, studies have shown that a significant 
number of TS patients are diagnosed in adulthood8 and these patients are also missed in this 
paediatric survey. 
Besides the initiation of GH treatment, early diagnosis has other potential advantages: the 
prevention of comorbidities (for example, hypertension), which may enhance the quality of life in 
these girls.9 Recurrent otitis media, resulting in chronic otitis media and progressive hearing loss 
needs an early and aggressive management.10 A history of middle ear disease in a girl with short 
stature should make the clinician aware of the possibility of Turner syndrome. Hence, we reconfirm 
our and others’ recommendation4 5 that a cytogenetic analysis is indicated in girls with 
unexplained short stature with their height more than 2 SD below the mean for age or below the 
parent specific lower limit of height.11 
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Table 1. Age and height at diagnosis in Belgian girls with Turner syndrome 
 2003 survey 1991 survey 
 All 45,X Others All 45,X Others 
Age at diagnosis (median (range)) 
All ages 6.6‡ (0.0-18.3) 1.2f† (0.0—17.5) 9.6* (0.0-18.3) 11.2 (0.0-17.4) 6.71 (0.0-17.0) 11.7 (0-17.4) 
Diagnosis >1 y 10.1† (1.1—18.3) 9.7* (1.1-17.5) 10.5* (1.4-18.3) 12.3 (1.6-17.4) 12.8 (1.6-17.0) 11.9 (3.9-17.4) 
Number (%) of patients per age category at diagnosis 
All ages 242 (100) 113 (47) 129 (53) 100 (100) 44 (44) 56 (56) 
<1 y 73 (30) 54 (22) 19(8) 15 (15) 13 (13) 2(2) 
1-12 y 115(48) 42(17) 73 (30) 40 (40) 13 (13) 27 (27) 
> 12 y 54(22) 17(7) 37 (15) 45 (45) 18 (18) 27 (27) 
Height SDS at diagnosis (mean (SD)) in patients aged 1 year or older at diagnosis 
<1 y 22.40 (0.93)‡ 22.26 (0.78)† 22.47 (0.99)* 22.90 (1.00) 23.04 (0.93) 22.82 (0.89) 
1-12 y 22.15(0.76) 22.10(0.74) 22.18 (0.76) 22.41 (0.86) 22.38 (1.00) 22.43 (0.79) 
> 12 y** 22.92(1.05)* 22.67(0.71)† 23.04 (1.15) 23.34 (0.99) 23.57 (0.99) 23.21 (0.82) 
*p<0.05; †p<0.01; ‡p<0.001: 2003 v 1991 survey. 
§p<0.05; ¶p<0.001: 45,X v other karyotypes. 
**All groups at p<0.01 level different from same group of 1-12 years. 
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